116 related articles for article (PubMed ID: 19156696)
1. Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR.
Gabellieri C; Beloueche-Babari M; Jamin Y; Payne GS; Leach MO; Eykyn TR
NMR Biomed; 2009 May; 22(4):456-61. PubMed ID: 19156696
[TBL] [Abstract][Full Text] [Related]
2. N-[2-bromocinnamyl(amino)ethyl]-5-isoquinolinesulphonamide (H-89) inhibits incorporation of choline into phosphatidylcholine via inhibition of choline kinase and has no effect on the phosphorylation of CTP:phosphocholine cytidylyltransferase.
Wieprecht M; Wieder T; Geilen CC
Biochem J; 1994 Jan; 297 ( Pt 1)(Pt 1):241-7. PubMed ID: 8280105
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
4. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Al-Saffar NM; Jackson LE; Raynaud FI; Clarke PA; Ramírez de Molina A; Lacal JC; Workman P; Leach MO
Cancer Res; 2010 Jul; 70(13):5507-17. PubMed ID: 20551061
[TBL] [Abstract][Full Text] [Related]
5. Choline kinase: an important target for cancer.
Janardhan S; Srivani P; Sastry GN
Curr Med Chem; 2006; 13(10):1169-86. PubMed ID: 16719778
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
Mignion L; Danhier P; Magat J; Porporato PE; Masquelier J; Gregoire V; Muccioli GG; Sonveaux P; Gallez B; Jordan BF
Int J Cancer; 2016 Apr; 138(8):2043-9. PubMed ID: 26595604
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity.
Hong BS; Allali-Hassani A; Tempel W; Finerty PJ; Mackenzie F; Dimov S; Vedadi M; Park HW
J Biol Chem; 2010 May; 285(21):16330-40. PubMed ID: 20299452
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells.
Nimmagadda S; Glunde K; Pomper MG; Bhujwalla ZM
Neoplasia; 2009 May; 11(5):477-84. PubMed ID: 19412432
[TBL] [Abstract][Full Text] [Related]
9. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Ramírez de Molina A; Báñez-Coronel M; Gutiérrez R; Rodríguez-González A; Olmeda D; Megías D; Lacal JC
Cancer Res; 2004 Sep; 64(18):6732-9. PubMed ID: 15374991
[TBL] [Abstract][Full Text] [Related]
10. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.
Gallego-Ortega D; Ramirez de Molina A; Ramos MA; Valdes-Mora F; Barderas MG; Sarmentero-Estrada J; Lacal JC
PLoS One; 2009 Nov; 4(11):e7819. PubMed ID: 19915674
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of Human Choline Kinase Beta by Protein Kinase A: Its Impact on Activity and Inhibition.
Chang CC; Few LL; Konrad M; See Too WC
PLoS One; 2016; 11(5):e0154702. PubMed ID: 27149373
[TBL] [Abstract][Full Text] [Related]
12. Direct inhibition of choline kinase by a near-infrared fluorescent carbocyanine.
Arlauckas SP; Popov AV; Delikatny EJ
Mol Cancer Ther; 2014 Sep; 13(9):2149-58. PubMed ID: 25028471
[TBL] [Abstract][Full Text] [Related]
13. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Glunde K; Jie C; Bhujwalla ZM
Cancer Res; 2004 Jun; 64(12):4270-6. PubMed ID: 15205341
[TBL] [Abstract][Full Text] [Related]
14. Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells.
Huang C; Hydo LM; Liu S; Miller RT
Cell Signal; 2009 Dec; 21(12):1894-900. PubMed ID: 19716891
[TBL] [Abstract][Full Text] [Related]
15. New non-symmetrical choline kinase inhibitors.
Schiaffino-Ortega S; López-Cara LC; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Espinosa A; Marco C; Entrena A
Bioorg Med Chem; 2013 Nov; 21(22):7146-54. PubMed ID: 24080101
[TBL] [Abstract][Full Text] [Related]
16. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells.
Mori N; Glunde K; Takagi T; Raman V; Bhujwalla ZM
Cancer Res; 2007 Dec; 67(23):11284-90. PubMed ID: 18056454
[TBL] [Abstract][Full Text] [Related]
17. [Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay.
Al-Saeedi F; Smith T; Welch A
Anticancer Res; 2007; 27(2):901-6. PubMed ID: 17465218
[TBL] [Abstract][Full Text] [Related]
18. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
19. A selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-bromocinnamyl(amino)ethyl]-5-isoquinolinesulfonamide (H-89), inhibits phosphatidylcholine biosynthesis in HeLa cells.
Geilen CC; Wieprecht M; Wieder T; Reutter W
FEBS Lett; 1992 Sep; 309(3):381-4. PubMed ID: 1516714
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling.
Yalcin A; Clem B; Makoni S; Clem A; Nelson K; Thornburg J; Siow D; Lane AN; Brock SE; Goswami U; Eaton JW; Telang S; Chesney J
Oncogene; 2010 Jan; 29(1):139-49. PubMed ID: 19855431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
